134 related articles for article (PubMed ID: 16009907)
21. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
22. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
[TBL] [Abstract][Full Text] [Related]
23. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a.
Schwid SR; Decker MD; Lopez-Bresnahan M;
Neurology; 2005 Dec; 65(12):1964-6. PubMed ID: 16380621
[TBL] [Abstract][Full Text] [Related]
24. [Increased plasma C-reactive protein in a pregnant woman with multiple sclerosis: corticotherapy or not ?].
Limelette A; Caucheteux N; Ramont L; Tourbah A; Maquart FX
Ann Biol Clin (Paris); 2010; 68(2):243-7. PubMed ID: 20348053
[TBL] [Abstract][Full Text] [Related]
25. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
[TBL] [Abstract][Full Text] [Related]
26. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion.
Loricchio ML; Cianfrocca C; Pasceri V; Bianconi L; Auriti A; Calo L; Lamberti F; Castro A; Pandozi C; Palamara A; Santini M
Am J Cardiol; 2007 May; 99(10):1421-4. PubMed ID: 17493472
[TBL] [Abstract][Full Text] [Related]
27. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
29. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis.
Chowdhury SA; Lin J; Sadiq SA
Arch Neurol; 2008 Feb; 65(2):232-5. PubMed ID: 18268193
[TBL] [Abstract][Full Text] [Related]
30. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
Cocco E; Marchi P; Floris G; Mascia MG; Deriu M; Sirca A; Mamusa E; Lai M; Mura M; Mallarini G; Marrosu MG
Funct Neurol; 2006; 21(3):145-9. PubMed ID: 17049133
[TBL] [Abstract][Full Text] [Related]
31. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
[TBL] [Abstract][Full Text] [Related]
32. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system.
Shapiro AM; Jack CS; Lapierre Y; Arbour N; Bar-Or A; Antel JP
Arch Neurol; 2006 Sep; 63(9):1296-9. PubMed ID: 16966508
[TBL] [Abstract][Full Text] [Related]
33. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.
Pakdaman H; Fallah A; Sahraian MA; Pakdaman R; Meysamie A
Neuropediatrics; 2006 Aug; 37(4):257-60. PubMed ID: 17177154
[TBL] [Abstract][Full Text] [Related]
34. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.
Snaedal S; Heimbürger O; Qureshi AR; Danielsson A; Wikström B; Fellström B; Fehrman-Ekholm I; Carrero JJ; Alvestrand A; Stenvinkel P; Bárány P
Am J Kidney Dis; 2009 Jun; 53(6):1024-33. PubMed ID: 19394732
[TBL] [Abstract][Full Text] [Related]
35. High-sensitivity C-reactive protein in the exhaled breath condensate and serum in stable and unstable asthma.
Zietkowski Z; Tomasiak-Lozowska MM; Skiepko R; Mroczko B; Szmitkowski M; Bodzenta-Lukaszyk A
Respir Med; 2009 Mar; 103(3):379-85. PubMed ID: 19010654
[TBL] [Abstract][Full Text] [Related]
36. Beneficial effect of interferon-beta treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-beta injection.
Nakatsuji Y; Nakano M; Moriya M; Kishigami H; Tatsumi C; Tada S; Sadahiro S; Naka T; Mitani K; Funauchi M; Azuma T; Watanabe S; Kinoshita M; Kajiyama K; Yuasa Y; Kaido M; Takahashi MP; Naba I; Hazama T; Sakoda S;
Cytokine; 2006 Oct; 36(1-2):69-74. PubMed ID: 17161613
[TBL] [Abstract][Full Text] [Related]
37. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
38. Repeated intervals of high-dose corticosteroid: an overlooked therapy in multiple sclerosis.
Johnson LN; Morey SS
Mo Med; 2005; 102(1):47-50. PubMed ID: 15754617
[TBL] [Abstract][Full Text] [Related]
39. Clinical parameters to predict response to interferon in relapsing multiple sclerosis.
Fromont A; Debouverie M; Le Teuff G; Quantin C; Binquet C; Moreau T
Neuroepidemiology; 2008; 31(3):150-6. PubMed ID: 18716412
[TBL] [Abstract][Full Text] [Related]
40. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
Banwell B; Tremlett H
Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]